# IZABRIGHT-Lung01: HCP commentary report

> 32 verified statements (12 from clinicians verified by NPI or staff page) from 13 commentary sources · 6 findings · updated Oct 29, 2026

## Report

- Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
- NCT ID: NCT07100080
- Registry: https://clinicaltrials.gov/study/NCT07100080
- Sponsor: Bristol-Myers Squibb
- Phase: Phase 2/Phase 3
- Status: Recruiting
- Drugs: carboplatin, cisplatin, pemetrexed
- Indications: Non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: 4424a0b982367f149bf411cae8ed4c9b9652c0bddaf62a632c8d65a5bc8ffb15

## Counts

- HCP commentary sources screened: 23
- Sources cited by verified statements: 14
- Verified statements: 32
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 12
- Findings: 6
- People found in screened sources: 11
- Voices cited: 11
- Cited voices identity-verified: 9
- Organisational or shared accounts (not counted as people): 1

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

IZABRIGHT-Lung01 tests izalontamab brengitecan against pemetrexed plus platinum chemotherapy in EGFR-mutated NSCLC progressing after third-generation EGFR-TKI treatment. In the sources reviewed for this edition, an X poster’s enthusiasm for global development remains conditional. External efficacy signals draw enthusiasm in an X post, while toxicity draws concern in an X post. The relevant treatment benchmark and efficacy ranking remain unresolved questions in these sources.

## Open Medical Affairs question

What benefit–toxicity evidence against the clinically relevant comparator would justify replacement rather than continued EGFR inhibition or another post-TKI option?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. A reported control-arm amendment makes the relevant treatment benchmark a live question
- F2. Favorable China evidence encourages global development, but does not settle efficacy ranking or survival benefit
- F3. Manageability judgments coexist with substantial severe toxicity and differing pulmonary-safety reports
- F4. Early-phase enthusiasm depends on cohort, prior treatment and the meaning of reported dose advancement
- F5. ADC substitution is not the only positioning question: sequencing and continued EGFR inhibition remain open
- F6. CNS activity and predictive selection are promising areas with unresolved evidence requirements

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 3 | 3 | 3 | 2 | none recorded | 2 |
| F2 | 9 | 5 | 5 | 5 | none recorded | 4 |
| F3 | 10 | 5 | 5 | 5 | recorded | 3 |
| F4 | 8 | 5 | 5 | 5 | none recorded | 4 |
| F5 | 4 | 4 | 4 | 4 | none recorded | 3 |
| F6 | 2 | 1 | 1 | 1 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 0 | 0 | 1 | 0 | 2 | 3 | 0 | 2 posts and articles, 1 registry | yes |
| F2 | 4 | 1 | 0 | 0 | 4 | 10 | 1 | 5 posts and articles | yes |
| F3 | 3 | 1 | 0 | 0 | 6 | 11 | 3 | 5 posts and articles | yes |
| F4 | 0 | 1 | 0 | 1 | 6 | 8 | 2 | 5 posts and articles | yes |
| F5 | 3 | 1 | 0 | 0 | 0 | 4 | 1 | 4 posts and articles | yes |
| F6 | 2 | 0 | 0 | 0 | 0 | 2 | 2 | 1 post or article | yes |

### Trial dimensions

- Primary endpoint: Recommended Phase 3 Dose (RP3D) of BMS-986507: F3 (3 shared claims), F4 (2 shared claims)
- Primary endpoint: Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR): F2 (4 shared claims), F3 (1 shared claims), F4 (1 shared claims)
- Secondary endpoints: F2 (4 shared claims), F3 (4 shared claims), F4 (4 shared claims)
- Population and setting: F2 (1 shared claims), F3 (2 shared claims), F4 (4 shared claims), F5 (3 shared claims)
- The comparison: F1 (1 shared claims), F2 (2 shared claims), F3 (1 shared claims), F5 (1 shared claims)
- Safety and tolerability: F2 (1 shared claims), F3 (9 shared claims), F4 (3 shared claims)
- Design and conduct: no finding draws on it directly

## Sample findings

Paraphrased; the full report links each statement to its source.

### F4. Early-phase enthusiasm depends on cohort, prior treatment and the meaning of reported dose advancement

How should treatment history shape interpretation of early-phase iza-bren activity? This question is explored through an X post.

Source: X thread, 2026-09-14.

### F1. A reported control-arm amendment makes the relevant treatment benchmark a live question

Which comparator should frame evaluation of iza-bren after EGFR-TKI progression? This question is examined through an X post.

Source: X thread, 2026-10-26.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 32 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 14 | Counts free |
| Speaker attribution for cited voices | 11 | Paid |

## Trial aspects

11 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Recommended Phase 3 Dose (RP3D) of BMS-986507 | discussed | 3 | 1 |
| Primary endpoint: Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR) | discussed | 5 | 4 |
| Secondary endpoints | discussed | 9 | 8 |
| Population and setting | discussed | 7 | 7 |
| The comparison | discussed | 5 | 5 |
| Safety and tolerability | discussed | 10 | 6 |
| Design and conduct | no commentary found | 0 | 0 |
| Sequencing, competing options and continued EGFR inhibition | discussed | 4 | 4 |
| Intracranial activity and brain-metastasis subgroup uncertainty | discussed | 1 | 1 |
| Predictive biomarkers and ADC construct-related questions | discussed | 1 | 1 |
| Global translatability, evidence maturity and regulatory interpretation | discussed | 6 | 3 |
| Research access and anticipated development timing | discussed | 3 | 3 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 22 | 13 |
| Bluesky threads | 1 | 0 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2025-09-09 to 2026-10-26
- Cited window: 2025-09-09 to 2026-10-26
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
- Registry: NCT07100080 (https://clinicaltrials.gov/study/NCT07100080)
- Study IDs: CA244-0010 · EU CTR (2025-521908-22) · WHO (U1111-1321-3429) · CA2440010 (Bristol-Myers Squibb Protocol ID)
- Sponsor: Bristol-Myers Squibb
- Design: Phase 2/Phase 3 · interventional, randomized, parallel, phase2, phase3
- Status: Recruiting
- Enrollment: 500 (estimated)
- Start: 2025-11-05 (actual)
- Primary completion: 2028-12-15 (estimated)
- Primary endpoint: Recommended Phase 3 Dose (RP3D) of BMS-986507 (Approximately 3 months after the first dose)
- Primary endpoint: Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR) (Up to 3 years)
- Intervention: Iza-bren (drug)
- Intervention: Carboplatin (drug)
- Intervention: Cisplatin (drug)
- Intervention: Pemetrexed (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on balancing efficacy and severe treatment-related toxicity when choosing treatment after EGFR-TKI progression.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 13 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The discussion reviewed is not a representative sample of HCP opinion. Reposts show circulation, not additional independently expressed agreement.
- No full protocol document or results publication for NCT07100080 was available. Favorable efficacy and safety statements concern PANKU-Lung01 or earlier development unless explicitly described otherwise.
- The reported chemotherapy-plus-amivantamab control option is a speaker's account of an amendment, not independently confirmed protocol information in this edition.
- Stock scope and the update relayed by a speaker name IZABRIGHT-Lung01 but list NCT05983432 rather than this report's NCT07100080. Their development and dose statements require that qualification.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The safety accounts concern different populations and studies, with differing ILD or pneumonitis descriptions. They do not support a pooled safety estimate or a general conclusion that pulmonary risk is absent.
- Drug-related regulatory coverage was incomplete, and no exact iza-bren label was identified. Regulatory-interest commentary does not establish approval or a labeled use.
- Site-opening plans, the approximately 2028 readout expectation and other forward-looking statements retain their original timing and uncertainty; subsequent events are not established here.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition

Last checked for new commentary 2026-10-29. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (32 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (9 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/izabright-lung01-nct07100080
- Agents: POST https://www.erudio.com/api/orders with {"report": "izabright-lung01-nct07100080", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=izabright-lung01-07100080

## Cite

Erudio Health. IZABRIGHT-Lung01 (NCT07100080): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/izabright-lung01-nct07100080

## Machine access

- JSON: https://www.erudio.com/reports/izabright-lung01-nct07100080.json
- Markdown: https://www.erudio.com/reports/izabright-lung01-nct07100080.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "izabright-lung01-07100080"}`